67 related articles for article (PubMed ID: 19004520)
1. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Lee CW; Murray N; Anderson H; Rao SC; Bishop W
Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
[TBL] [Abstract][Full Text] [Related]
3. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS; Forde PM; Hughes B; Sun Z; Brown C; Ramalingam S; Cook A; Lesterhuis WJ; Yip S; O'Byrne K; Pavlakis N; Brahmer J; Anagnostou V; Ford K; Fitzpatrick K; Bricker A; Cummins MM; Stockler M; Nowak AK;
BMJ Open; 2022 Jan; 12(1):e057663. PubMed ID: 35078853
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.
de Fonseka D; Morley A; Stadon L; Keenan E; Walker S; Smith S; Harvey JE; Cox RA; Dangoor A; Comins C; Rogers C; Edey A; Addeo A; Maskell NA
Trials; 2018 Aug; 19(1):467. PubMed ID: 30157910
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Malignant Pleural Mesothelioma.
de Gooijer CJ; Borm FJ; Scherpereel A; Baas P
Front Oncol; 2020; 10():187. PubMed ID: 32154179
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D
J Thorac Oncol; 2024 Jan; 19(1):166-172. PubMed ID: 37567387
[TBL] [Abstract][Full Text] [Related]
9. Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients.
Goričar K; Holcar M; Mavec N; Kovač V; Lenassi M; Dolžan V
J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683154
[TBL] [Abstract][Full Text] [Related]
10. Novel systemic therapy against malignant pleural mesothelioma.
Mancuso MR; Neal JW
Transl Lung Cancer Res; 2017 Jun; 6(3):295-314. PubMed ID: 28713675
[TBL] [Abstract][Full Text] [Related]
11. Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.
Goričar K; Kovač V; Dolžan V
Sci Rep; 2017 Apr; 7():46537. PubMed ID: 28422153
[TBL] [Abstract][Full Text] [Related]
12. Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma.
Goričar K; Kovač V; Franko A; Dodič-Fikfak M; Dolžan V
Dis Markers; 2015; 2015():316739. PubMed ID: 26451067
[TBL] [Abstract][Full Text] [Related]
13. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma.
Kovac V; Dodic-Fikfak M; Arneric N; Dolzan V; Franko A
Radiol Oncol; 2015 Sep; 49(3):279-85. PubMed ID: 26401134
[TBL] [Abstract][Full Text] [Related]
14. Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.
Saint-Pierre MD; Pease C; Mithoowani H; Zhang T; Nicholas GA; Laurie SA; Wheatley-Price P
Lung Cancer Int; 2015; 2015():590148. PubMed ID: 26316950
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
Ak G; Metintas S; Akarsu M; Metintas M
BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
Goricar K; Kovac V; Dolzan V
Radiol Oncol; 2014 Jun; 48(2):163-72. PubMed ID: 24991206
[TBL] [Abstract][Full Text] [Related]
17. Management of malignant pleural mesothelioma-The European experience.
Opitz I
J Thorac Dis; 2014 May; 6 Suppl 2(Suppl 2):S238-52. PubMed ID: 24868442
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
Haas AR; Sterman DH
Clin Chest Med; 2013 Mar; 34(1):99-111. PubMed ID: 23411061
[TBL] [Abstract][Full Text] [Related]
19. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.
Kovac V; Zwitter M; Zagar T
Radiol Oncol; 2012 Jun; 46(2):136-44. PubMed ID: 23077450
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
